Opthea Limited (ASX:OPT)
Australia
· Delayed Price · Currency is AUD | Market Cap | 738.77M |
| Revenue (ttm) | 336.08K |
| Net Income (ttm) | -403.04M |
| Shares Out | 1.23B |
| EPS (ttm) | -0.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,141,489 |
| Average Volume | 4,653,062 |
| Open | 0.605 |
| Previous Close | 0.600 |
| Day's Range | 0.595 - 0.615 |
| 52-Week Range | 0.335 - 1.165 |
| Beta | 1.64 |
| RSI | 22.25 |
| Earnings Date | May 28, 2025 |
About Opthea
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company’s lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit V... [Read more]
Financial Performance
In 2024, Opthea's revenue was $261,859, a decrease of -32.03% compared to the previous year's $385,275. Losses were -$220.24 million, 54.5% more than in 2023.
Financial numbers in USD Financial StatementsNews
Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty
On Monday, Opthea Limited (NASDAQ: OPT) released results from its global Phase 3 clinical trial COAST in patients with wet age-related macular degeneration (wet AMD) . The trial evaluated the efficac...
Investors fret over clinical trial failure’s hit on Regal funds
Phil King’s investment firm was the largest shareholder in Opthea, the eye treatment play that could become insolvent after a poor medical result.
Opthea Announces COAST Phase 3 Trial Topline Results
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on t...
ASX 200 LIVE: UBS upgrades FMG; OPT in crisis talks after drug trial fails, shares suspended; sharemarket falls.
Shares fall; UBS neutral on Fortescue; Opthea drug trial spurs crisis talks; MinRes resumes Onslow haulage; James Hardie, Helia drop; $A, gold lower.
It’s Phil King’s Regal against the shorts at biotech play Opthea
The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial clinical trial, shorts are rising.
Opthea Announces Phase 2b Wet AMD Publication
Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., ...
Opthea to Present at Oppenheimer Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therap...
Opthea Wet AMD Data Featured at Macula Society Meeting
MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea: Small Australian Company Aiming To Upend The Wet AMD Market
Opthea to Host Investor Days in New York and Australia
Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on Februar...
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia an...
Opthea's Wet AMD Program to be Featured at FLORetina 2024
MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel thera...
Opthea Appoints Kathy Connell to Board of Directors
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J.,...
Opthea's Wet AMD Program Featured at Ophthalmology Events
17 Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024 Ophthalmology Innovation Summit XIV, November 23, 2024 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 12, 2024 (GLOBE NEW...
Opthea Limited: Major Catalyst In Early 2025 For Complementary Eye Disease Candidate
Opthea Wet AMD Program to be Presented at Innovate Retina
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea appoints Tom Reilly as CFO
Opthea appoints experienced CFO Tom Reilly and chief medical officer Parisa Zamiri as the company prepares for a new phase.
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea joins S&P/ASX 300 index
Opthea (OPT) joins the S&P/ASX 300 Index, enhancing its market visibility and potentially attracting more investors.
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 202...
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...
Opthea appoints Daniel Geffken as interim CFO
Opthea Announces Executive Leadership Changes and Senior Hires
Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access MELBOU...
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel ther...